Arbutus Biopharma Q1 2024 Update
Ticker: ABUS · Form: 10-Q · Filed: 2024-05-02T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biopharma
TL;DR
Arbutus Biopharma filed its Q1 2024 10-Q, showing operational data. Check financials for details.
AI Summary
Arbutus Biopharma Corp. reported its first quarter 2024 results, ending March 31, 2024. The company's financial statements indicate a period of operational activity, with specific figures for collaboration and contracts, and non-cash royalties. Further details on their financial position are available in the full 10-Q filing.
Why It Matters
This filing provides insight into Arbutus Biopharma's financial performance and operational status for the first quarter of 2024, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: medium — Biopharmaceutical companies often carry medium risk due to the inherent uncertainties in drug development and regulatory approvals.
Key Numbers
- 20240331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is provided.)
- 20240502 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Arbutus Biopharma Corp. (company) — Filer of the 10-Q report.
- TEKMIRA PHARMACEUTICALS Corp (company) — Former name of Arbutus Biopharma Corp.
- 20240331 (date) — End of the reporting period for the 10-Q.
- 20240502 (date) — Filing date of the 10-Q.
FAQ
What were the specific dollar amounts for 'CollaborationAndContractsMember' and 'NonCashRoyaltyMember' for the first quarter of 2024?
The provided text does not contain the specific dollar amounts for 'CollaborationAndContractsMember' and 'NonCashRoyaltyMember' for the first quarter of 2024, only the reporting periods.
What is the fiscal year end for Arbutus Biopharma Corp.?
The fiscal year end for Arbutus Biopharma Corp. is December 31 (1231).
When did Arbutus Biopharma Corp. change its name from TEKMIRA PHARMACEUTICALS Corp?
Arbutus Biopharma Corp. changed its name from TEKMIRA PHARMACEUTICALS Corp on June 7, 2011 (20110607).
What is the Standard Industrial Classification (SIC) code for Arbutus Biopharma Corp.?
The Standard Industrial Classification (SIC) code for Arbutus Biopharma Corp. is 2834, which corresponds to Pharmaceutical Preparations.
What is the business phone number listed for Arbutus Biopharma Corp.?
The business phone number listed for Arbutus Biopharma Corp. is 604-419-3200.
From the Filing
0001447028-24-000038.txt : 20240502 0001447028-24-000038.hdr.sgml : 20240502 20240502163218 ACCESSION NUMBER: 0001447028-24-000038 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 24909024 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 10-Q 1 abus-20240331.htm 10-Q abus-20240331 false 0001447028 12/31 2024 Q1 0001447028 2024-01-01 2024-03-31 0001447028 2024-04-30 xbrli:shares 0001447028 2024-03-31 iso4217:USD 0001447028 2023-12-31 0001447028 abus:CollaborationAndContractsMember 2024-01-01 2024-03-31 0001447028 abus:CollaborationAndContractsMember 2023-01-01 2023-03-31 0001447028 abus:NonCashRoyaltyMember 2024-01-01 2024-03-31 0001447028 abus:NonCashRoyaltyMember 2023-01-01 2023-03-31 0001447028 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0001447028 us-gaap:CommonStockMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001447028 us-gaap:RetainedEarningsMember 2023-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001447028 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001447028 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001447028 us-gaap:CommonStockMember 2024-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001447028 us-gaap:RetainedEarningsMember 2024-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001447028 us-gaap:CommonStockMember 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001447028 us-gaap:RetainedEarningsMember 2022-12-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001447028 2022-12-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001447028 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001447028 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001447028 us-gaap:CommonStockMember 2023-03-31 0001447028 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001447028 us-gaap:RetainedEarningsMember 2023-03-31 0001447028 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001447028 2023-03-31 abus:subsidiary 0001447028 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001447028 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001447028 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001447028 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001447028 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001447028 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001447028 us-gaap:MoneyMarketFundsMember us-gaap:CashAndCashEquivalents